ovarian adnexal mass Aspira Q4 Revenues Up 11 Percent, Firm Inks Deal for Ovarian Cancer Detection Tech The agreement is with the Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz. InterVenn Biosciences to Develop Cancer Tests, Expand Services Business With New Funding Premium The glycoproteomics firm is using its mass spec platform for ovarian cancer and immunotherapy tests as well as service work for pharma and other partners. Aspira Eyes $11M in Private Equity Financing Investors in the company, formerly known as Vermillion, have agreed to purchase $11 million in unregistered common stock at a price of $3.50 per share. Vermillion Q4 Revenues Up 123 Percent The company posted an 11 percent year-over-year decline in OVA1 sales but more than doubled its average revenue per test, to $301 from $143 in Q4 2015. Vermillion, Quest Extend, Amend Ovarian Cancer Test Deal The firms extended their OVA1 commercialization agreement an additional year while adding procedures for verifying the number of tests performed under the deal. Mar 7, 2017 Vermillion's Aspira Labs Secures Expanded Medi-Cal Coverage for OVA1 Mar 2, 2017 Vermillion's Aspira Labs Wins Coverage from BCBS of Michigan for OVA1 Nov 10, 2016 Vermillion Q3 Revenues Up 89 Percent Sep 29, 2016 Vermillion's Aspira Labs Wins Coverage from CareFirst BCBS for OVA1 Aug 19, 2016 Vermillion Hoping New Service Business Will Boost Revenue Growth Premium Aug 10, 2016 Vermillion Q2 Revenues Up 33 Percent, OVA1 Sales Down May 16, 2016 Vermillion Q1 Revenues Down 47 Percent Apr 28, 2016 Clinical Utility Study Finds Vermillion's OVA1 Useful in Driving High-Risk Patients to Specialists Apr 18, 2016 Vermillion Receives First $2M of $4M Loan From State of Connecticut Mar 24, 2016 With OVA1 Sales Slumping, Vermillion Looks Ahead to Overa Premium Mar 24, 2016 Vermillion Posts $361K in Q4 Revenues, Large Drop in OVA1 Sales Volume Mar 21, 2016 Vermillion Receives FDA 510(k) Clearance for Overa Jan 22, 2016 Consortium Publishes Study on Ultrasound Approach to Evaluate Adnexal Masses Premium Dec 1, 2015 Vermillion Wins Medi-Cal Coverage for OVA1 Nov 20, 2015 Vermillion's Kaiser Collaboration Could Hold Keys to Broadening OVA1 Uptake Premium Nov 12, 2015 Vermillion Q3 Revenues Up 2 Percent Oct 30, 2015 With CE Mark, Vermillion Moving Toward Commercialization of Overa Test Premium Oct 26, 2015 Vermillion Receives CE Mark for Overa Jul 13, 2015 Vermillion's Aspira Labs Receives New York State Clinical Lab Permit Breaking News Pediatric Medulloblastoma Subgroups May Benefit from Lower-Dose Radiation Therapy Space Radiation Shows Limited Effects on Mammalian Sperm DNA, Fertility Bluestar Genomics Sues Former Consultant, Ludwig Institute for Cancer Research Over IP Ownership New Products Posted to GenomeWeb: 10x Genomics, Swift Biosciences, Agilent Technologies, More In Brief This Week: Quantum-Si, TGen, Yale, and More People in the News: New Appointments at Invitae, PGDx, Oxford Nanopore, PacBio, More The Scan Fertility Fraud Found Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today. Ties Between Vigorous Exercise, ALS in Genetically At-Risk People Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports. Test Warning The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK. Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.